Waltham, United States
Mustang Bio, a clinical-stage bio-pharmaceutical entity founded in 2015, is strategically positioned within the United States as a specialized player in Biotechnology and Pharmaceutical industries. As a "A fortress biotech Company," Mustang is at the forefront of advancing medical breakthroughs through the development of cutting-edge cell and gene therapies.
The company's focus is on leveraging CAR T and CRISPR/Cas9-enhanced CAR T therapies to target a broad range of cancers, alongside its work on a lentiviral gene therapy for XSCID. Significant partnerships with leading medical institutions underscore Mustang's commitment to innovation and clinical progress.
As of its last financial activity on 01 February 2025, Mustang secured an $8.00M Post IPO Equity investment, highlighting ongoing investor confidence in its potential to address significant unmet medical needs and generate impactful therapeutic solutions.
